Sirtuin Inhibitor

Tenovin-D3 hydrochloride is a sirtuin SirT2 inhibitor that increases p21 (CDKN1A) expression in a p53 independent manner.

NCO-141 is a selective SIRT2 inhibitor with an IC₅₀ of 0.5 μM. NCO-141 induces cell apoptosis via caspase activation and mitochondrial superoxide anion production. NCO-141 induces cell autophagy by increasing LC3-II levels and autophagosome accumulation. NCO-141 is applicable to relevant research on leukemia.

Schisanhenol (Standard) (Schizanhenol (Standard)) is the analytical standard of Schisanhenol (HY-N0859). This product is intended for research and analytical applications. Schisanhenol, a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits UGT2B7 activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration.

Sirt2-IN-6 (compound 24a) potent and selective inhibitor of SIRT2, with an IC₅₀ of 0.815 μM. Sirt2-IN-6 can be used for the research of cancer.

Nicotinamide hydrochloride is a form of vitamin B3 or niacin. Nicotinamide hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide hydrochloride also inhibits SIRT1. Nicotinamide hydrochloride increases cellular NAD₊, ATP, ROS levels. Nicotinamide hydrochloride inhibits tumor growth and improves survival. Nicotinamide hydrochloride also has anti-HBV activity.

hsa62 is a dual inhibitor for SIRT1 and SIRT2, with IC₅₀ of 1.3 and 5.5 μM, respectively.

SIRT5 inhibitor 8 (compound 10) is a competitive inhibitor (IC₅₀: 5.38 μM) of sirtuin SIRT5 with anticancer potential.

Sirt2-IN-7 (compound 22) is a selective inhibitor of SIRT2. Sirt2-IN-7 inhibits SIRT2 with an IC₅₀ value and a K_i value of 178.2 nM and 154.3 nM, respectively. Sirt2-IN-7 can be used for the research of cancer.

SIRT5 Inhibitor 6 is a potent, substrate-competitive and selective SIRT5 inhibitor with an IC₅₀ of 3.0 μM. SIRT5 Inhibitor6 has a therapeutic potential against septic AKI in vivo.

CypD-IN-5 (compound C-9) is a potent cyclophilin D (CypD) inhibitor. CypD-IN-5 can be used in the study of Alzheimer's disease.

C1A is a class I/II HDACs and sirtuin inhibitor with an IC₅₀ of 479 nM for HDAC6. C1A induces sustained acetylation of HDAC6 substrates, α-tubulin and HSP90. C1A shows srtong anticancer effcts, and induces apoptosis in cancer cells.

Nicotinamide (GMP) (Niacinamide (GMP)) is the GMP level of Nicotinamide (HY-B0150). GMP guidelines are used to produce Nicotinamide (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.

YM-08 (Compounds 7a) is a brain-penetrant inhibitors of SIRT2,with the IC₅₀ of 19.9 μM. YM-08 also is inhibitor of Hsp70.

SIRT5 inhibitor 5 is a potent SIRT5 inhibitor with an IC₅₀ value of 0.21 µM. SIRT5 inhibitor 5 does not occupy the NNAD⁺ -binding pocket and acts as a substrate-competitive inhibitor.

SIRT2-IN-12 (Compound 3) is a SIRT2 inhibitor with a IC₅₀ value of 50 μM.

SIRT5 inhibitor 9 (compound 14) is a competitive inhibitor (IC₅₀: 4.07 μM) of sirtuin SIRT5 with anticancer potential.

Sirt1/CXCR3-IN-1 is a dual Sirt1/CXCR3 inhibitor with an IC₅₀ of 0.77 μM against Sirt1. Sirt1/CXCR3-IN-1 inhibits dengue virus replication, upregulates the expression of interferon-stimulated genes, and enhances the antiviral defense capacity of the host. Sirt1/CXCR3-IN-1 suppresses CXCR3-mediated T cell chemotaxis and cytokine release, thereby reducing immune activation and inflammatory responses. Sirt1/CXCR3-IN-1 is applicable to research related to dengue virus infection.

Sirt7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sirt7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mz325 is a dual inhibitor of HDAC and Sirt2, with the IC₅₀ of 9.7 μM to Sirt2, that play an important role in pathogenesis of cancer and neurodegeneration.

Sirt1/2-IN-1 (Compound 7) is a SIRT1 and SIRT2 inhibitor with IC₅₀ values of 1.81, 2.10 and 20.5 µg/mL against SIRT1, SIRT2 and SIRT3, respectively. Sirt1/2-IN-1 displays activity in hyperacetylation of α-tubulin protein with an IC₅₀ of 32.05 µg/mL. Sirt1/2-IN-1 shows prominent anticancer activity.